<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25897826</article-id><article-id pub-id-type="pmc">4404801</article-id><article-id pub-id-type="pii">srep09918</article-id><article-id pub-id-type="doi">10.1038/srep09918</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV
Non-Small Cell Lung Cancer: A Randomized, Phase III Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Xiaowen</given-names></name><xref ref-type="aff" rid="a1">1</xref><xref ref-type="author-notes" rid="n1">*</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="a2">2</xref><xref ref-type="author-notes" rid="n1">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Kuo</given-names></name><xref ref-type="aff" rid="a1">1</xref><xref ref-type="author-notes" rid="n1">*</xref></contrib><contrib contrib-type="author"><name><surname>Shang</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="a3">3</xref><xref ref-type="author-notes" rid="n1">*</xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Yuan</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Xiaochang</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Huimin</given-names></name><xref ref-type="aff" rid="a4">4</xref></contrib><contrib contrib-type="author"><name><surname>Geng</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="a5">5</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="a6">6</xref></contrib><contrib contrib-type="author"><name><surname>Dang</surname><given-names>Yazheng</given-names></name><xref ref-type="aff" rid="a7">7</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Enxiao</given-names></name><xref ref-type="aff" rid="a8">8</xref></contrib><contrib contrib-type="author"><name><surname>Ti</surname><given-names>Xinyu</given-names></name><xref ref-type="aff" rid="a9">9</xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Fulin</given-names></name><xref ref-type="aff" rid="a10">10</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yingqi</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Meng</given-names></name><xref ref-type="corresp" rid="c2">b</xref><xref ref-type="aff" rid="a11">11</xref></contrib><aff id="a1"><label>1</label><institution>State Key Laboratory of Cancer Biology, Biotechnology Center,
School of Pharmacy, The Fourth Military Medical University</institution>,
Xi'an, <country>China</country></aff><aff id="a2"><label>2</label><institution>Department of Oncology, Tangdu Hospital, The Fourth Military
Medical University</institution>, Xi'an, <country>China</country></aff><aff id="a3"><label>3</label><institution>Department of Health Statistics, School of Public Health, The
Fourth Military Medical University</institution>, Xi'an, <country>China</country></aff><aff id="a4"><label>4</label><institution>The Affiliated Cancer Hospital of Xinjiang Medical
University</institution>, Urumqi, <country>China</country></aff><aff id="a5"><label>5</label><institution>Department of Medical Oncology, General Hospital of Nanjing
Military Command, Medical School of Nanjing University</institution>, Nanjing,
<country>China</country></aff><aff id="a6"><label>6</label><institution>General Hospital of Ningxia Medical University</institution>, Yinchuan,
<country>China</country></aff><aff id="a7"><label>7</label><institution>Cancer Center, The 323 Hospital of People's Liberation
Army</institution>, Xi'an, <country>China</country></aff><aff id="a8"><label>8</label><institution>Department of Medical Oncology, First Affiliated Hospital of
Medical College, Xi'an Jiaotong University</institution>, Xi'an,
<country>China</country></aff><aff id="a9"><label>9</label><institution>Department of Respiratory Medicine, Xijing Hospital, The Fourth
Military Medical University</institution>, Xi'an, <country>China</country></aff><aff id="a10"><label>10</label><institution>New Taihe Biopharmaceutical Co.</institution>, Ltd.,
Guangzhou, <country>China</country></aff><aff id="a11"><label>11</label><institution>Department of Pharmacogenomics, School of Pharmacy, The Fourth
Military Medical University</institution>, Xi'an, <country>China</country></aff></contrib-group><author-notes><corresp id="c1"><label>a</label>
<email>lemon781106@hotmail.com</email>
</corresp><corresp id="c2"><label>b</label>
<email>zhangyqh@fmmu.edu.cn</email>
</corresp><fn id="n1"><label>*</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>21</day><month>04</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>4</volume><elocation-id>9918</elocation-id><history><date date-type="received"><day>27</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>23</day><month>03</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014, Macmillan Publishers Limited. All rights reserved</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Macmillan Publishers Limited. All rights reserved</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this article are
included in the article's Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative
Commons license, users will need to obtain permission from the license holder in
order to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><abstract><p>Tumor necrosis factor (TNF), an anti-angiogenic agent in cancer treatment, is limited
to isolated limb perfusion due to systemic toxicities. We previously prepared a TNF
mutant (rmhTNF) that significantly improved responses in lung cancer patients and
exhibited a promising safety profile in phase I and II studies. To further
investigate whether rmhTNF with standard chemotherapy provides a survival benefit,
529 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) were randomly
assigned to receive docetaxel plus carboplatin/cisplatin with rmhTNF (265) or
chemotherapy alone (264). After four cycles of treatment, the median overall
survival was 13.7 months in the chemotherapy plus rmhTNF group compared with 10.3
months in the chemotherapy group (hazard ratio (HR) 0.75, <italic>P</italic> = 0.001). The
median progression-free survival in the chemotherapy plus rmhTNF group and the
chemotherapy group was 8.6 and 4.5 months (HR 0.76, <italic>P</italic> = 0.001), respectively,
with corresponding response rates of 38.5% and 27.7% (<italic>P</italic> = 0.008). Increased
hyperpyrexia and pulmonary hemorrhage were associated with rmhTNF, but most effects
were well tolerated. The results indicated that rmhTNF effectively potentiated
chemotherapy in patients with advanced NSCLC and was comparable with bevacizumab, an
angiogenesis inhibitor approved by the Food and Drug Administration (FDA) for
NSCLC.</p></abstract></article-meta></front><body><p>Non-small cell lung cancer (NSCLC), a leading cause of cancer death, is often diagnosed
at advanced stages when few treatment options are available<xref ref-type="bibr" rid="b1">1</xref><xref ref-type="bibr" rid="b2">2</xref>. Although
modest progress has been made with the use of platinum-based combination chemotherapy,
additional treatment methods are needed<xref ref-type="bibr" rid="b3">3</xref><xref ref-type="bibr" rid="b4">4</xref>. Angiogenesis is a hallmark
of cancer<xref ref-type="bibr" rid="b5">5</xref>. Anti-angiogenic therapy can destroy or
&#x02018;normalize' excessive and abnormal blood vessels in the tumor,
thereby potentiating the effects of chemotherapy by improving the delivery of drugs and
oxygen<xref ref-type="bibr" rid="b6">6</xref>. Bevacizumab (Avastin, Genentech/Roche, San Francisco, CA,
US), a monoclonal antibody against vascular endothelial growth factor (VEGF), was
approved by the Food and Drug Administration (FDA) for the treatment of stage IIIB/IV
non-squamous NSCLC in combination with paclitaxel and carboplatin in 2006<xref ref-type="bibr" rid="b7">7</xref>. The approval and the associated pivotal study proved that anti-angiogenic therapy is
useful in advanced NSCLC<xref ref-type="bibr" rid="b8">8</xref><xref ref-type="bibr" rid="b9">9</xref>.</p><p>Tumor necrosis factor (TNF) is a monocyte-derived cytokine that stimulates the acute
phase reaction of the immune system. Its abilities to destroy tumor vasculature, induce
hemorrhagic necrosis in specific tumor types and synergize with various chemotherapy
reagents were established two decades ago<xref ref-type="bibr" rid="b10">10</xref><xref ref-type="bibr" rid="b11">11</xref><xref ref-type="bibr" rid="b12">12</xref>. However, as an
immune stimulator and endogenous pyrogen, TNF is implicated in septic shock, cachexia
and fever<xref ref-type="bibr" rid="b13">13</xref><xref ref-type="bibr" rid="b14">14</xref>. The maximum tolerable dose of TNF in patients is 10-fold
lower than the effective antitumor dose<xref ref-type="bibr" rid="b15">15</xref><xref ref-type="bibr" rid="b16">16</xref><xref ref-type="bibr" rid="b17">17</xref>. The clinical
application of TNF has been limited to the isolated limb perfusion (ILP) setting for
soft tissue sarcoma (STS) and melanoma in-transit metastases confined to the limb.
Systemic toxicity is abolished by limb isolation and the resulting extra-corporeal
circulation<xref ref-type="bibr" rid="b18">18</xref><xref ref-type="bibr" rid="b19">19</xref>. An approximately 100% response rate acquired by
ILP with TNF and melphalan in patients with STS has inspired various strategies to
minimize the toxicities of TNF for its application as a systemic anti-cancer drug<xref ref-type="bibr" rid="b20">20</xref><xref ref-type="bibr" rid="b21">21</xref><xref ref-type="bibr" rid="b22">22</xref>.</p><p>We previously prepared a recombinant mutated human TNF (rmhTNF, NAX&#x000ae;) featuring
the deletion of the first seven amino acids and substitution of four amino acids (Arg
for Pro at position 8, Lys for Ser at position 9, Arg for Asp at position 10, and Phe
for Leu at position 157). rmhTNF exhibits 25-fold increased antitumor effects and at
least a 50-fold increased LD50 (50% lethal dose) compared with wild type TNF<xref ref-type="bibr" rid="b23">23</xref><xref ref-type="bibr" rid="b24">24</xref>. In previous phase I and II studies, rmhTNF plus chemotherapy
achieved a 48.89% response rate compared with 17.78% for chemotherapy alone (<italic>P</italic>
&#x0003c; 0.001) in patients with advanced NSCLC, and most adverse events (AEs) were well
tolerated<xref ref-type="bibr" rid="b25">25</xref>.</p><p>The NCD-ANSCLC (NAX&#x000ae; with Carboplatin/Cisplatin and Docetaxel in Advanced
Non-Small Cell Lung Cancer) phase III trial was conducted to confirm phase II results.
The primary objective was to compare overall survival (OS) of the rmhTNF and
chemotherapy combination with standard chemotherapy. Progression-free survival (PFS),
response rate (RR), survival rates and safety assessments were also reported.</p><sec disp-level="1" sec-type="results"><title>Results</title><p>An independent data monitoring committee reviewed the data and recommended the
release of the study results in March 2012, given that the criteria for significance
pre-specified in the protocol had been achieved. The results reported here include
follow-up through December 2012 (median follow-up was 15.8 months for the
chemotherapy plus rmhTNF group and 13.6 months for the chemotherapy alone group).
The patients lost during follow-up were included in disease progression or death
data.</p><sec disp-level="2"><title>Population Characteristics</title><p>Between January 2007 and April 2010, 529 patients were randomly assigned to
receive chemotherapy plus rmhTNF (n = 265) or chemotherapy alone (n = 264).
Demographic and baseline characteristics were balanced between the treatment
arms (<xref ref-type="table" rid="t1">Table 1</xref>). No significant differences were noted
regarding patient characteristics in various strata. In addition, 19 and 32
patients discontinued treatment in the chemotherapy plus rmhTNF and chemotherapy
groups, respectively, due to disease progression, adverse events, refusal or
other reasons (<xref ref-type="fig" rid="f1">Fig. 1</xref>). Five patients in the chemotherapy
plus rmhTNF group and 3 patients in the chemotherapy group were lost to
follow-up. Only 1 patient in the chemotherapy group was not followed. The most
common follow-up therapy administered was chemotherapy (post-study treatment).
More patients in the chemotherapy group (70%) received follow-up therapies than
in the chemotherapy plus rmhTNF group (58%).</p></sec><sec disp-level="2"><title>Efficacy</title><p>The primary analysis consisted of all randomly assigned patients (the
intention-to-treat population, ITT). The median OS was 13.7 months [95%
confidence intervals (CI) 12.34&#x02013;15.06] for the chemotherapy
plus rmhTNF group compared with 10.6 months [95% CI
9.27&#x02013;11.94] for the chemotherapy group (hazard ratio, HR 0.75
[95% CI 0.63&#x02013;0.89], <italic>P</italic> = 0.001, <xref ref-type="fig" rid="f2">Fig. 2A</xref>). The median PFS was 8.6 months [95% CI
7.05&#x02013;10.14] for the chemotherapy plus rmhTNF group and 4.5
months [95% CI 3.39&#x02013;5.61] for the chemotherapy group
(HR 0.76 [95% CI 0.64&#x02013;0.90], <italic>P</italic> = 0.001, <xref ref-type="fig" rid="f2">Fig. 2B</xref>). Secondary end points including RR, response
duration and survival rates are presented in <xref ref-type="table" rid="t2">Table 2</xref>. In
total, 102 (38.5%) patients in the chemotherapy plus rmhTNF group and 73 (27.7%)
in the chemotherapy group exhibited a CR (complete response) or PR (partial
response). The RR of the combination group was significantly increased compared
with the chemotherapy group (odd ratio (OR) 1.64 [95% CI
1.14&#x02013;2.36], <italic>P</italic> = 0.008). The median response duration
was 5.8 months (interquartile range (IQR) 3.6&#x02013;11) for the chemotherapy
plus rmhTNF group and 4.1 months (IQR 2.8&#x02013;9.8) for the chemotherapy
group. At 1 year, 147 (55.5%) patients in the chemotherapy plus rmhTNF group
survived compared with 111 (42%) in the chemotherapy group (OR 1.72
[95% CI 1.22&#x02013;2.42], <italic>P</italic> = 0.002). At 4 years,
18 (6.8%) patients in the chemotherapy plus rmhTNF group survived compared with
1 (0.4%) in the chemotherapy group (OR 19.17 [95% CI
2.54&#x02013;144.65], <italic>P</italic> &#x0003c; 0.001). No significant
differences were observed between the survival rates of the two arms at 2 and 3
years.</p></sec><sec disp-level="2"><title>Subgroup Analyses</title><p>Regarding male patients, the median OS of the chemotherapy plus rmhTNF group was
14.0 months [95% CI 12.53&#x02013;15.47] compared with 10.9
months [95% CI 8.92&#x02013;12.88] in the chemotherapy group
(HR 0.74 [95% CI 0.60&#x02013;0.92], <italic>P</italic> = 0.007). For
current and former smokers (who stopped smoking less than 5 years ago), the
median OS of the chemotherapy plus rmhTNF group was 14.6 months [95% CI
13.52&#x02013;15.68] compared with 9.8 months [95% CI
7.61&#x02013;12.0] in the chemotherapy group (HR 0.70 [95%
CI 0.55&#x02013;0.88], <italic>P</italic> = 0.002). In PS 1 (European
Cooperative Oncology Group, ECOG performance status) patients, the median OS of
the chemotherapy plus rmhTNF group was 14.5 months [95% CI
9.81&#x02013;15.19] compared with 10.9 months [95% CI
6.06&#x02013;11.94] in the chemotherapy group (HR 0.70 [95%
CI 0.57&#x02013;0.86], <italic>P</italic> = 0.001). For patients with stage
IIIB disease, the median OS of the chemotherapy plus rmhTNF group was 14.0
months [95% CI 12.19&#x02013;15.81] compared with 10.7
months [95% CI 9.04&#x02013;12.36] in the chemotherapy group
(HR 0.75 [95% CI 0.60&#x02013;0.93], <italic>P</italic> = 0.007). In
patients with adenocarcinoma, the median OS of the chemotherapy plus rmhTNF
group was 13.5 months [95% CI 11.73&#x02013;15.27] compared
with 9.0 months [95% CI 6.29&#x02013;11.71] in the
chemotherapy group (HR 0.69 [95% CI 0.54&#x02013;0.89],
<italic>P</italic> = 0.004). For patients who previously underwent surgery, the median
OS of the chemotherapy plus rmhTNF group was 14.8 months [95% CI
12.74&#x02013;16.86] compared with 9.9 months [95% CI
8.22&#x02013;11.58] in the chemotherapy group (HR 0.72
[95%CI 0.57&#x02013;0.91], <italic>P</italic> = 0.005). When
carboplatin was administered, the median OS of the chemotherapy plus rmhTNF
group was 14.0 months [95% CI 12.43&#x02013;15.57] compared
with 10.7 months [95% CI 9.16&#x02013;12.24] in the
chemotherapy group (HR 0.77 [95% CI 0.64&#x02013;0.92],
<italic>P</italic> = 0.004). When cisplatin was administered, the median OS of the
chemotherapy plus rmhTNF group was 12.6 months [95% CI
9.85&#x02013;15.50] compared with 9.0 months [95% CI
1.72-12.72] in the chemotherapy group (HR 0.48 [95% CI
0.25&#x02013;0.93], <italic>P</italic> = 0.024). No significant differences
were observed between the two arms for females, never smokers (including those
who stopped smoking more than 5 years previously), PS 0 patients, patients with
stage IV disease, and patients with diseases other than adenocarcinoma. In
patients who previously received radiotherapy, chemotherapy and/or biological
therapy, no significant differences were observed (<xref ref-type="fig" rid="f2">Fig.
2C</xref>, <xref ref-type="fig" rid="f2">2D</xref>). However, HR analyses revealed that rmhTNF
was beneficial in all the subgroups assessed if CIs were not considered. The HRs
of the median OS based on patient stratification are summarized in <xref ref-type="fig" rid="f3">Figure 3</xref>. The most significant benefit was noted in current
and former smokers, patients with adenocarcinoma and patients administered
cisplatin.</p></sec><sec disp-level="2"><title>Safety</title><p>All patients who received the study treatment (261 in the chemotherapy plus
rmhTNF group and 259 in the chemotherapy group) were included in the analysis of
toxic effects. <xref ref-type="table" rid="t3">Table 3</xref> presents the rates of adverse
events (AEs) in each treatment group. Most AEs were grade 1 or 2. Incidences of
grade 3 and 4 pyrexia (drug-related fever), flu-like symptoms and hematemesis
were significantly increased in chemotherapy plus rmhTNF group compared with the
chemotherapy group (<italic>P</italic> &#x0003c; 0.05). These events were considered rmhTNF
related. In the chemotherapy plus rmhTNF group, 7 patients withdrew due to
pyrexia, and 3 withdrew due to neutropenia. In the chemotherapy group, 3
patients withdrew due to neutropenia. Diarrhea, rash, arrhythmia and albuminuria
were the most common AEs noted in the two groups.</p><p>Fatal AEs were reported in ten patients. Seven were reported with chemotherapy
plus rmhTNF, and three were reported with chemotherapy alone. Of the seven fatal
AEs in the combination group, 3 were attributed to pulmonary hemorrhage
(hematemesis), 2 to hypotension, 1 to pulmonary embolism and 1 to myocardial
infarction. The three fatal AEs in the chemotherapy group included 2 cardiac
events and 1 pulmonary embolism. Pulmonary hemorrhage and hypotension were
considered rmhTNF related. Cardiac events were considered paclitaxel related.
Other fatal AEs were deemed unrelated to the treatment.</p></sec></sec><sec disp-level="1" sec-type="discussion"><title>Discussion</title><p>Unlike normal blood vessels, tumor-associated vasculature is poorly organized and
hyper-permeable<xref ref-type="bibr" rid="b5">5</xref>. As a result, interstitial hypertension exists
within solid tumors. Interstitial hypertension and compression from cancer cells
greatly compromises the delivery and effectiveness of conventional cytotoxic
therapies<xref ref-type="bibr" rid="b26">26</xref>. Based on the death domain of the TNF receptor 1, TNF
induces excessive apoptosis in endothelial cells and pericytes, which results in
pruning of tumor vessels and a decrease in interstitial hypertension<xref ref-type="bibr" rid="b27">27</xref>. These effects facilitate the augmented distribution of the drug in the tumor and
better exposure of the tumor cells to the cytostatic agent<xref ref-type="bibr" rid="b18">18</xref><xref ref-type="bibr" rid="b28">28</xref>. The
addition of TNF-&#x003b1; improves the accumulation of chemotherapeutic drugs
selectively in the tumor up to three- to six-fold in rat models. However, the wide
expression of TNF receptors in the immune system and the downstream NF-&#x003ba;B
stimulation signals caused uncontrollable hyperpyrexia when TNF-&#x003b1; was used
as an anti-angiogenic agent in cancer treatment<xref ref-type="bibr" rid="b29">29</xref>. rmhTNF has a
specific activity of 1 &#x000d7; 10<sup>9</sup>&#x02005;unit/mg defined by
the standard lysis method (actinomycin D-treated mouse L929 cells), which is at
least 50-fold higher than TNF. The dose adopted in our studies (4 &#x000d7;
10<sup>6</sup>&#x02005;unit/m<sup>2</sup>/day) was actually
4&#x02005;&#x000b5;g/m<sup>2</sup>/day after undergoing calculations
based on activity. Moderate side effects of rmhTNF were promised, as 100 to
400&#x02005;&#x000b5;g/m<sup>2</sup>/day was considered effective for
wild-type TNF<xref ref-type="bibr" rid="b30">30</xref><xref ref-type="bibr" rid="b31">31</xref>. In the present study, most side effects were
well tolerated, and only 3 patients discontinued treatment due to fever. Pulmonary
hemorrhage was another AE of special concern in our study. Hemorrhage is common in
anti-angiogenic treatments. The incidence of life-threatening pulmonary hemorrhage
was approximately 2% for bevacizumab in the treatment of patients with advanced,
non-squamous NSCLC<xref ref-type="bibr" rid="b8">8</xref>. Therefore, hemoptysis was an exclusion criterion
in the present study and should be monitored carefully.</p><p>Our results indicated that the addition of rmhTNF to a standard platinum-based
chemotherapy regimen improved OS (13.7 months vs. 10.6 months, HR 0.75, <italic>P</italic> =
0.001). In addition, rmhTNF prolonged PFS and improved the RR and one-year survival
rate. The benefits of rmhTNF were comparable to bevacizumab, which significantly
improved the survival of patients with advanced NSCLC when combined with
chemotherapy (12.3 months vs. 10.3 months, HR 0.79, <italic>P</italic> = 0.003)<xref ref-type="bibr" rid="b8">8</xref>. Patients in our study received four cycles of therapy, whereas most patients in
bevacizumab trials were administered at least five cycles of combination treatment
and long-term maintenance with monoclonal antibody. From the perspective of
treatment costs, rmhTNF was more acceptable than monoclonal antibody for Chinese
patients.</p><p>In the present study, OS improvements with rmhTNF were not consistent among all
pre-specified stratification groups. Although the median OS was improved with rmhTNF
plus chemotherapy versus chemotherapy alone, the differences were not statistically
significant in some strata (<xref ref-type="fig" rid="f2">Fig. 2D</xref>). However, HR analyses
according to baseline characteristics indicated that rmhTNF was beneficial in all
the subgroups assessed if CIs were not considered (<xref ref-type="fig" rid="f3">Fig. 3</xref>).
Possible explanations for this flaw include imbalances between the two groups with
respect to known or unknown baseline prognostic factors, imbalances in the use of
off-study therapies, statistical chance, or a true difference.</p><p>In conclusion, the addition of rmhTNF to a platinum-based, two-agent chemotherapy
regimen conferred significant improvement in OS, PFS, RR and survival rate in NSCLC
patients with a good performance status. Increased toxic effects, particularly
hyperpyrexia and pulmonary hemorrhage, were associated with the addition of rmhTNF.
These risks must be considered and monitored carefully when administering rmhTNF
plus docetaxel and carboplatin/cisplatin for the treatment of patients with
NSCLC.</p></sec><sec disp-level="1" sec-type="methods"><title>Patients and Methods</title><sec disp-level="2"><title>Study Design and Population</title><p>NCD-ANSCLC was a multi-center, randomized, double-blind, phase III study
comparing rmhTNF with docetaxel plus carboplatin or cisplatin versus
chemotherapy alone in patients with stage IIIB/IV NSCLC. The study was performed
in 6 hospitals in China. Eligible patients (&#x02265; 18 years) were required to
have histologically or cytologically confirmed stage IIIB/IV NSCLC. Other
inclusion criteria were measurable lesions as defined by the Response Evaluation
Criteria in Solid Tumors (RECIST version 3.0), a European Cooperative Oncology
Group (ECOG) PS of 0 or 1, predicted life expectancy &#x02265; 12 weeks from
first study-drug dose, and adequate hematologic, hepatic, cardiac and renal
function. A washout period from previous treatments was required (2 to 6 weeks).
Exclusion criteria included hemoptysis (1/2 tsp or more per event); central
nervous system metastases; pregnancy or lactation; a history of documented
hemorrhagic diathesis or coagulopathy; therapeutic anticoagulation; regular use
of aspirin (&#x0003e; 325&#x02005;mg/day), non-steroidal anti-inflammatory
agents, or other agents known to inhibit platelet function; a history of
hypersensitivity to paclitaxel, polypeptide drugs or biologics; and previous
exposure to taxanes.</p><p>The study was approved by the ethics committee of each participating center (the
Ethics Committee of West China Center of Medical Sciences, Sichuan University;
the Ethics Committee of the Fourth Military Medical University; the Ethics
Committee of Xinjiang Medical University; the Ethics Committee of Ningxia
Medical University; the Ethics Committee of the First Affiliated Hospital of
Medical College, Xi'an Jiaotong University; the Ethics Committee of
the General Hospital of Nanjing Military Command) and complied with the
Declaration of Helsinki and Good Clinical Practice guidelines. All patients
provided written informed consent before any study-related procedure.</p><p>This trial is registered with Chictr.org (Chinese Clinical Trial Registry; number
ChiCTR-IPR-14005500).</p></sec><sec disp-level="2"><title>Randomization and Masking</title><p>Research coordinators at each center randomly assigned eligible patients in a 1:1
ratio by use of a clinical trial randomization system<xref ref-type="bibr" rid="b32">32</xref>. The
system could minimized imbalance between treatment groups within each stratum
and generated a unique number for each patient. These numbers were reported to
the hospital staff when patients were assigned. In turn, the hospital staff
referred to a manual of unique numbers generated by an independent statistician
prior to study activation to determine the study treatment allocated to the
randomized patient. Study investigators, research coordinators, attending care
teams, the patients and their families were blinded to treatment allocation.</p></sec><sec disp-level="2"><title>Procedures</title><p>Randomly assigned patients received four cycles of docetaxel
(75&#x02005;mg/m<sup>2</sup> on day 1 of a 3 week cycle; intravenous
(IV)) and platinum chemotherapy (carboplatin 5 &#x000d7; area under the curve
or cisplatin 75&#x02005;mg/m<sup>2</sup> on day 1 of a 3 week cycle, IV)
plus rmhTNF (4 &#x000d7; 10<sup>6</sup>&#x02005;units?m<xref ref-type="bibr" rid="b2">2</xref>?day on days 1-7 and days 11-17 of each cycle, intramuscular (IM))
(chemotherapy plus rmhTNF group) or docetaxel and platinum (chemotherapy group).
Treatment discontinuation or interruption due to AEs could occur at any time.
Dosing could be interrupted for a maximum of 2 weeks if clinically indicated. At
disease progression, treatment was unmasked. Patients in the chemotherapy group
could continue or receive further treatment at their investigator's
discretion. Patients in the chemotherapy plus rmhTNF group were required to
discontinue treatment.</p></sec><sec disp-level="2"><title>Assessments and End Points</title><p>All patients were hospitalized for frequent monitoring of clinical signs during
treatments. AEs and clinically significant laboratory abnormalities were
recorded according to the National Cancer Institute Common Terminology Criteria
for Adverse Events (version 3.0). After baseline evaluation, tumor responses
were assessed by use of CT (computed tomography) with RECIST every 6 weeks for
the treatment period, every 12 weeks for the first two years of follow-up, and
then every 24 weeks until disease progression or death. An independent review
committee of clinicians and radiologists masked to patient assignment reviewed
all images and determined tumor response and progression status.</p><p>The primary efficacy end point was OS (the time from random assignment to death
from any cause). Secondary end points included PFS (the time from randomization
to documented disease progression or death), RR (CR+PR), response duration and
survival rate.</p></sec><sec disp-level="2"><title>Statistical Analysis</title><p>All efficacy analyses were based on a comparison of the assigned treatments. The
primary analysis comprised all randomly assigned patients (ITT). The safety
population consisted of all patients who received at least one dose of the study
drug and were subject to at least one post-baseline safety assessment. Based on
an OS of 10.3 months in the control group of the previous study<xref ref-type="bibr" rid="b8">8</xref>,
approximately 382 deaths were required to detect a HR of 0.75 (chemotherapy plus
rmhTNF vs. chemotherapy alone) at 80% power with a two-sided log-rank test and
an &#x003b1;-level of 5%. Accounting for patient ineligibility and withdrawal
(approximately 15%), 529 patients were required.</p><p>Event-time distributions were estimated by the Kaplan-Meier method. Cox
proportional-hazards models, stratified according to the disease stages, tumor
histology, smoking status, chemotherapy reagents and prior therapies, were used
to estimate HRs and to test for significance of the timing of events. The
proportional hazard assumptions of the data were tested before Cox regression
analysis. The method and results of the proportional hazard assumption test were
shown in the <xref ref-type="supplementary-material" rid="s1">supplementary information</xref>. Responses, survival
rates, ORs and AEs were analyzed using Fisher's exact tests.
Zelen's test for homogeneity of ORs across strata was performed to
validate data. All reported P-values are two-sided, and CIs are at the 95%
level.</p></sec><sec disp-level="2"><title>Role of the Funding Source</title><p>This trial was funded by New Taihe Biopharmaceutical Co., Ltd., Guangzhou, China
and was designed and monitored by the Clinical Pharmacology Department of West
China Center of Medical Sciences, Sichuan University. Data were gathered,
analyzed, and interpreted by New Taihe as well as all authors and investigators.
The corresponding author had full access to the study data and took full
responsibility for the final decision to submit the report for publication.</p></sec></sec><sec disp-level="1"><title>Author Contributions</title><p>Y. Z., M. L. and F. F. designed the study and coordinated the distributions of
patients and the participant nurses in six hospitals. X. M., K. Z., Y. G., L. S., X.
Z., W. Z. and X. X. collected data, performed the statistical analysis and prepared
all tables and figures. X. M. and Y. S. wrote the main manuscript text. Y. S., H.
J., J. G., Y. D., E. L., X. T. participated in the assignments of patients and
follow up. All authors reviewed and approved the final manuscript.</p></sec><sec sec-type="supplementary-material" id="s1"><title>Supplementary Material</title><supplementary-material id="d33e22" content-type="local-data"><caption><title>Supplementary Information</title><p>Supplementary Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep09918-s1.pdf"/></supplementary-material></sec></body><back><ref-list><ref id="b1"><mixed-citation publication-type="journal"><name><surname>Jemal</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>Global cancer statistics</article-title>. <source>C.A. Cancer J. Clin.</source>
<volume>61</volume>, <fpage>69</fpage>&#x02013;<lpage>90</lpage> (<year>2011</year>).</mixed-citation></ref><ref id="b2"><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>F.</given-names></name>, <name><surname>Cole</surname><given-names>P.</given-names></name> &#x00026; <name><surname>Bina</surname><given-names>W.
F.</given-names></name>
<article-title>Time trend and geographic patterns of lung adenocarcinoma in the United
States, 1973-2002</article-title>. <source>Cancer Epidemiol. Biomarkers Prev.</source>
<volume>16</volume>, <fpage>2724</fpage>&#x02013;<lpage>2729</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">18086779</pub-id></mixed-citation></ref><ref id="b3"><mixed-citation publication-type="journal"><name><surname>Peters</surname><given-names>S.</given-names></name>
<italic>et al.</italic>
<article-title>Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann.
Oncol.</source>
<volume>7</volume>, <fpage>56</fpage>&#x02013;<lpage>64</lpage> (<year>2012</year>).</mixed-citation></ref><ref id="b4"><mixed-citation publication-type="journal"><name><surname>Schiller</surname><given-names>J. H.</given-names></name>
<italic>et al.</italic>
<article-title>Comparison of four chemotherapy regimens for advanced non-small-cell lung
cancer</article-title>. <source>N. Engl. J. Med.</source>
<volume>346</volume>, <fpage>92</fpage>&#x02013;<lpage>98</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">11784875</pub-id></mixed-citation></ref><ref id="b5"><mixed-citation publication-type="journal"><name><surname>Carmeliet</surname><given-names>P.</given-names></name> &#x00026;
<name><surname>Jain</surname><given-names>R. K.</given-names></name>
<article-title>Angiogenesis in cancer and other diseases</article-title>. <source>Nature.</source>
<volume>407</volume>, <fpage>249</fpage>&#x02013;<lpage>257</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">11001068</pub-id></mixed-citation></ref><ref id="b6"><mixed-citation publication-type="journal"><name><surname>Jain</surname><given-names>R. K.</given-names></name>
<article-title>Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm
for combination therapy</article-title>. <source>Nat. Med.</source>
<volume>7</volume>, <fpage>987</fpage>&#x02013;<lpage>989</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11533692</pub-id></mixed-citation></ref><ref id="b7"><mixed-citation publication-type="other">FDA Approved Drug Products. , <italic>FDA. Drugs Web site</italic>, (2006). Available
at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/SCRIPTS/CDER/DRUGSATFDA/INDEX.CFM">http://www.accessdata.fda.gov/SCRIPTS/CDER/DRUGSATFDA/INDEX.CFM</ext-link>.
[Access: 8th October 2014]</mixed-citation></ref><ref id="b8"><mixed-citation publication-type="journal"><name><surname>Sandler</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung
cancer</article-title>. <source>N. Engl. J. Med.</source>
<volume>355</volume>, <fpage>2542</fpage>&#x02013;<lpage>2550</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">17167137</pub-id></mixed-citation></ref><ref id="b9"><mixed-citation publication-type="journal"><name><surname>Lopez-Chavez</surname><given-names>A.</given-names></name>
<italic>et al.</italic>
<article-title>Bevacizumab maintenance in patients with advanced non-small-cell lung
cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology
Group 4599 Study: results of an exploratory analysis</article-title>. <source>J. Thorac.
Oncol.</source>
<volume>7</volume>, <fpage>1707</fpage>&#x02013;<lpage>1712</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">23059774</pub-id></mixed-citation></ref><ref id="b10"><mixed-citation publication-type="journal"><name><surname>Watanabe</surname><given-names>N.</given-names></name>
<italic>et al.</italic>
<article-title>Toxic effect of tumor necrosis factor on tumor vasculature in mice</article-title>.
<source>Cancer Res.</source>
<volume>48</volume>, <fpage>2179</fpage>&#x02013;<lpage>2183</lpage> (<year>1988</year>).<pub-id pub-id-type="pmid">3349488</pub-id></mixed-citation></ref><ref id="b11"><mixed-citation publication-type="journal"><name><surname>Folli</surname><given-names>S.</given-names></name>
<italic>et al.</italic>
<article-title>Tumor-necrosis factor can enhance radio-antibody uptake in human colon
carcinoma xenografts by increasing vascular permeability</article-title>. <source>Int. J.
Cancer.</source>
<volume>53</volume>, <fpage>829</fpage>&#x02013;<lpage>836</lpage> (<year>1993</year>).<pub-id pub-id-type="pmid">8449608</pub-id></mixed-citation></ref><ref id="b12"><mixed-citation publication-type="journal"><name><surname>Brouckaert</surname><given-names>P.</given-names></name>
<italic>et al.</italic>
<article-title>Tumor necrosis factor-alpha augmented tumor response in B16BL6
melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil)
correlates with altered Doxil pharmacokinetics</article-title>. <source>Int. J.
Cancer.</source>
<volume>109</volume>, <fpage>442</fpage>&#x02013;<lpage>448</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">14961585</pub-id></mixed-citation></ref><ref id="b13"><mixed-citation publication-type="journal"><name><surname>Locksley</surname><given-names>R. M.</given-names></name>,
<name><surname>Killeen</surname><given-names>N.</given-names></name> &#x00026;
<name><surname>Lenardo</surname><given-names>M. J.</given-names></name>
<article-title>The TNF and TNF receptor superfamilies: integrating mammalian
biology</article-title>. <source>Cell.</source>
<volume>104</volume>, <fpage>487</fpage>&#x02013;<lpage>501</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11239407</pub-id></mixed-citation></ref><ref id="b14"><mixed-citation publication-type="journal"><name><surname>Kriegler</surname><given-names>M.</given-names></name>, <name><surname>Perez</surname><given-names>C.</given-names></name>, <name><surname>DeFay</surname><given-names>K.</given-names></name>,
<name><surname>Albert</surname><given-names>I.</given-names></name> &#x00026;
<name><surname>Lu</surname><given-names>S. D.</given-names></name>
<article-title>A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane
protein: ramifications for the complex physiology of TNF</article-title>.
<source>Cell.</source>
<volume>53</volume>, <fpage>45</fpage>&#x02013;<lpage>53</lpage> (<year>1988</year>).<pub-id pub-id-type="pmid">3349526</pub-id></mixed-citation></ref><ref id="b15"><mixed-citation publication-type="journal"><name><surname>Skillings</surname><given-names>J.</given-names></name>
<italic>et al.</italic>
<article-title>A phase II study of recombinant tumor necrosis factor in renal cell
carcinoma: a study of the National Cancer Institute of Canada Clinical
Trials Group</article-title>. <source>J. Immunother (1991).</source>
<volume>11</volume>, <fpage>67</fpage>&#x02013;<lpage>70</lpage> (<year>1992</year>).<pub-id pub-id-type="pmid">1734950</pub-id></mixed-citation></ref><ref id="b16"><mixed-citation publication-type="journal"><name><surname>Schiller</surname><given-names>J. H.</given-names></name>
<italic>et al.</italic>
<article-title>Biological and clinical effects of intravenous tumor necrosis factor-alpha
administered three times weekly</article-title>. <source>Cancer Res.</source>
<volume>51</volume>, <fpage>1651</fpage>&#x02013;<lpage>1658</lpage> (<year>1991</year>).<pub-id pub-id-type="pmid">1998956</pub-id></mixed-citation></ref><ref id="b17"><mixed-citation publication-type="journal"><name><surname>Saks</surname><given-names>S.</given-names></name>, <name><surname>Rosenblum</surname><given-names>M.</given-names></name>
<article-title>Recombinant human TNF-alpha: preclinical studies and results from early
clinical trials</article-title>. <source>Immunol. Ser.</source>
<volume>56</volume>, <fpage>567</fpage>&#x02013;<lpage>587</lpage> (<year>1992</year>).<pub-id pub-id-type="pmid">1550875</pub-id></mixed-citation></ref><ref id="b18"><mixed-citation publication-type="journal"><name><surname>Lejeune</surname><given-names>F. J.</given-names></name>,
<name><surname>Li&#x000e9;nard</surname><given-names>D.</given-names></name>,
<name><surname>Matter</surname><given-names>M.</given-names></name>,
<name><surname>R&#x000fc;egg</surname><given-names>C.</given-names></name>
<article-title>Efficiency of recombinant human TNF in human cancer therapy</article-title>.
<source>Cancer Immun.</source>
<volume>6</volume>, <fpage>6</fpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16551058</pub-id></mixed-citation></ref><ref id="b19"><mixed-citation publication-type="journal"><name><surname>Deroose</surname><given-names>J. P.</given-names></name>
<italic>et al.</italic>
<article-title>20 years experience of TNF-based isolated limb perfusion for in-transit
melanoma metastases: TNF dose matters</article-title>. <source>Ann. Surg. Oncol.</source>
<volume>19</volume>, <fpage>627</fpage>&#x02013;<lpage>635</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">21879272</pub-id></mixed-citation></ref><ref id="b20"><mixed-citation publication-type="journal"><name><surname>Gregorc</surname><given-names>V.</given-names></name>
<italic>et al.</italic>
<article-title>Phase Ib study of NGR-hTNF, a selective vascular targeting agent,
administered at low doses in combination with doxorubicin to patients with
advanced solid tumours</article-title>. <source>Br. J. Cancer.</source>
<volume>101</volume>, <fpage>219</fpage>&#x02013;<lpage>224</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19568235</pub-id></mixed-citation></ref><ref id="b21"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>H.</given-names></name>
<italic>et al.</italic>
<article-title>Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein</article-title>.
<source>Mol. Cancer Ther.</source>
<volume>7</volume>, <fpage>1044</fpage>&#x02013;<lpage>1053</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18483294</pub-id></mixed-citation></ref><ref id="b22"><mixed-citation publication-type="journal"><name><surname>Varfolomeev</surname><given-names>E.</given-names></name>
<italic>et al.</italic>
<article-title>IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation,
and TNFalpha-dependent apoptosis</article-title>. <source>Cell.</source>
<volume>131</volume>, <fpage>669</fpage>&#x02013;<lpage>681</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">18022362</pub-id></mixed-citation></ref><ref id="b23"><mixed-citation publication-type="journal"><name><surname>Yan</surname><given-names>Z.</given-names></name>
<italic>et al.</italic>
<article-title>A mutated human tumor necrosis factor-alpha improves the therapeutic index
in vitro and in vivo</article-title>. <source>Cytotherapy.</source>
<volume>8</volume>, <fpage>415</fpage>&#x02013;<lpage>423</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16923618</pub-id></mixed-citation></ref><ref id="b24"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Safety evaluation and pharmacokinetics of a novel human tumor necrosis
factor-alpha exhibited a higher antitumor activity and a lower systemic
toxicity</article-title>. <source>Anticancer Drugs.</source>
<volume>21</volume>, <fpage>243</fpage>&#x02013;<lpage>251</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20166241</pub-id></mixed-citation></ref><ref id="b25"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>M.</given-names></name>
<italic>et al.</italic>
<article-title>Phase II multicenter, randomized, double-blind study of recombinant mutated
human tumor necrosis factor-alpha in combination with chemotherapies in
cancer patients</article-title>. <source>Cancer Sci.</source>
<volume>103</volume>, <fpage>288</fpage>&#x02013;<lpage>295</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22085427</pub-id></mixed-citation></ref><ref id="b26"><mixed-citation publication-type="journal"><name><surname>Jain</surname><given-names>R. K.</given-names></name>
<article-title>The next frontier of molecular medicine: delivery of therapeutics</article-title>.
<source>Nat. Med.</source>
<volume>4</volume>, <fpage>655</fpage>&#x02013;<lpage>657</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">9623964</pub-id></mixed-citation></ref><ref id="b27"><mixed-citation publication-type="journal"><name><surname>Van Horssen</surname><given-names>R.</given-names></name>, <name><surname>Ten
Hagen</surname><given-names>T. L.</given-names></name> &#x00026;
<name><surname>Eggermont</surname><given-names>A. M.</given-names></name>
<article-title>TNF-alpha in cancer treatment: molecular insights, antitumor effects, and
clinical utility</article-title>. <source>Oncologist.</source>
<volume>11</volume>, <fpage>397</fpage>&#x02013;<lpage>408</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16614236</pub-id></mixed-citation></ref><ref id="b28"><mixed-citation publication-type="journal"><name><surname>van der Veen</surname><given-names>A. H.</given-names></name>
<italic>et al.</italic>
<article-title>TNF-alpha augments intratumoural concentrations of doxorubicin in
TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances
anti-tumour effects</article-title>. <source>Br. J. Cancer.</source>
<volume>82</volume>, <fpage>973</fpage>&#x02013;<lpage>980</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10732774</pub-id></mixed-citation></ref><ref id="b29"><mixed-citation publication-type="journal"><name><surname>Wajant</surname><given-names>H.</given-names></name>,
<name><surname>Pfizenmaier</surname><given-names>K.</given-names></name> &#x00026; Scheurich
P. . <article-title>Tumor necrosis factor signaling</article-title>. <source>Cell Death Differ.</source>
<volume>10</volume>, <fpage>45</fpage>&#x02013;<lpage>65</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12655295</pub-id></mixed-citation></ref><ref id="b30"><mixed-citation publication-type="journal"><name><surname>Furman</surname><given-names>W. L.</given-names></name>
<italic>et al.</italic>
<article-title>Phase I clinical trial of recombinant human tumor necrosis factor in
children with refractory solid tumors: a Pediatric Oncology Group
study</article-title>. <source>J. Clin. Oncol.</source>
<volume>11</volume>, <fpage>2205</fpage>&#x02013;<lpage>2210</lpage> (<year>1993</year>).<pub-id pub-id-type="pmid">8229135</pub-id></mixed-citation></ref><ref id="b31"><mixed-citation publication-type="journal"><name><surname>Starnes</surname><given-names>C. O.</given-names></name>
<article-title>Coley's toxins in perspective</article-title>. <source>Nature.</source>
<volume>357</volume>, <fpage>11</fpage>&#x02013;<lpage>12</lpage> (<year>1992</year>).<pub-id pub-id-type="pmid">1574121</pub-id></mixed-citation></ref><ref id="b32"><mixed-citation publication-type="other">Clinical Trail Randomization System. . Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://random.302cr.net/">http://random.302cr.net/</ext-link>
[Access: 4th February 2015]</mixed-citation></ref></ref-list></back><floats-group><fig id="f1"><label>Figure 1</label><caption><title>Enrollment, randomization, and follow-up of study patients.</title><p>Chemotherapy = docetaxel plus carboplatin or cisplatin; rmhTNF, recombinant
mutated human tumor necrosis factor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep09918-f1"/></fig><fig id="f2"><label>Figure 2</label><caption><title>Kaplan-Meier curves of the pre-specified stratification populations.</title><p>(A) Overall survival in the intention-to-treat population. (B)
Progression-free survival in the intention-to-treat population. (C) Overall
survival in populations whose median survival exhibited significant
differences after rmhTNF plus chemotherapy treatment or chemotherapy alone
(<italic>P</italic> &#x0003c; 0.05). (D) Overall survival in the populations whose
median survival did not exhibit significant differences after rmhTNF plus
chemotherapy treatment or chemotherapy alone (<italic>P</italic> &#x0003e; 0.05).
Chemotherapy = docetaxel plus carboplatin or cisplatin; rmhTNF, recombinant
mutated human tumor necrosis factor; CI, confidence intervals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep09918-f2"/></fig><fig id="f3"><label>Figure 3</label><caption><title>Forest plot of hazard ratios for overall survival assessed by subgroup
factors.</title><p>Horizontal lines represent confidence intervals (CI). ECOG PS, Eastern
Cooperative Oncology Group Performance Status.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep09918-f3"/></fig><table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Baseline Patient Demographic and Clinical Characteristics</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">Chemotherapy plus rmhTNF (N = 265) No. (%)</th><th align="center" valign="top" charoff="50">Chemotherapy (N = 264) No. (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age (years)</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median</td><td align="center" valign="top" charoff="50">54.2</td><td align="center" valign="top" charoff="50">55.6</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Range</td><td align="center" valign="top" charoff="50">27-69</td><td align="center" valign="top" charoff="50">28-70</td></tr><tr><td align="left" valign="top" charoff="50">Sex</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="char" valign="top" char="(" charoff="50">170 (64)</td><td align="char" valign="top" char="(" charoff="50">164 (62)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="char" valign="top" char="(" charoff="50">95 (36)</td><td align="char" valign="top" char="(" charoff="50">100 (38)</td></tr><tr><td align="left" valign="top" charoff="50">Smoking status</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Current and Former</td><td align="char" valign="top" char="(" charoff="50">140 (53)</td><td align="char" valign="top" char="(" charoff="50">143 (54)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Never</td><td align="char" valign="top" char="(" charoff="50">125 (47)</td><td align="char" valign="top" char="(" charoff="50">121 (46)</td></tr><tr><td align="left" valign="top" charoff="50">Stage of disease</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;IIIB</td><td align="char" valign="top" char="(" charoff="50">175 (66)</td><td align="char" valign="top" char="(" charoff="50">174 (66)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;IV</td><td align="char" valign="top" char="(" charoff="50">90 (34)</td><td align="char" valign="top" char="(" charoff="50">90 (34)</td></tr><tr><td align="left" valign="top" charoff="50">Histological type</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Adenocarcinoma</td><td align="char" valign="top" char="(" charoff="50">125 (47)</td><td align="char" valign="top" char="(" charoff="50">126 (48)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Squamous cell carcinoma Large
&#x02003;cell carcinoma Others</td><td align="char" valign="top" char="(" charoff="50">140 (53)</td><td align="char" valign="top" char="(" charoff="50">138 (52)</td></tr><tr><td align="left" valign="top" charoff="50">ECOG PS</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;0</td><td align="char" valign="top" char="(" charoff="50">69 (26)</td><td align="char" valign="top" char="(" charoff="50">74 (28)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1</td><td align="char" valign="top" char="(" charoff="50">196 (74)</td><td align="char" valign="top" char="(" charoff="50">190 (72)</td></tr><tr><td align="left" valign="top" charoff="50">Chemotherapy regimen</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Docetaxel + Carboplatin</td><td align="char" valign="top" char="(" charoff="50">241 (91)</td><td align="char" valign="top" char="(" charoff="50">246 (93)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Docetaxel + Cisplatin</td><td align="char" valign="top" char="(" charoff="50">24 (9)</td><td align="char" valign="top" char="(" charoff="50">18 (7)</td></tr><tr><td align="left" valign="top" charoff="50">Time since diagnosis (weeks)</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median (Range)</td><td align="char" valign="top" char="(" charoff="50">10.2 (1&#x02013;79)</td><td align="char" valign="top" char="(" charoff="50">11 (1&#x02013;146)</td></tr><tr><td align="left" valign="top" charoff="50">Prior therapy</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Chemotherapy</td><td align="char" valign="top" char="(" charoff="50">148 (56)</td><td align="char" valign="top" char="(" charoff="50">145 (55)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Surgery</td><td align="char" valign="top" char="(" charoff="50">138 (52)</td><td align="char" valign="top" char="(" charoff="50">156 (59)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Biologic therapy (monoclonal
&#x02003;antibodies, vaccines)</td><td align="char" valign="top" char="(" charoff="50">64 (24)</td><td align="char" valign="top" char="(" charoff="50">66 (25)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Radiotherapy</td><td align="char" valign="top" char="(" charoff="50">29 (11)</td><td align="char" valign="top" char="(" charoff="50">24 (9)</td></tr><tr><td align="left" valign="top" charoff="50">Follow-up anticancer therapy</td><td align="center" valign="top" charoff="50">N = 260</td><td align="center" valign="top" charoff="50">N = 260</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Any therapy</td><td align="char" valign="top" char="(" charoff="50">150 (58)</td><td align="char" valign="top" char="(" charoff="50">181 (70)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Chemotherapy</td><td align="char" valign="top" char="(" charoff="50">116 (45)</td><td align="char" valign="top" char="(" charoff="50">130 (50)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Radiotherapy</td><td align="char" valign="top" char="(" charoff="50">15 (6)</td><td align="char" valign="top" char="(" charoff="50">21 (8)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Biologic therapy</td><td align="char" valign="top" char="(" charoff="50">44 (17)</td><td align="char" valign="top" char="(" charoff="50">59 (23)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Surgery</td><td align="char" valign="top" char="(" charoff="50">8 (3)</td><td align="char" valign="top" char="(" charoff="50">5 (2)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Unknown</td><td align="char" valign="top" char="(" charoff="50">27 (10)</td><td align="char" valign="top" char="(" charoff="50">8 (3)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>ECOG PS: Eastern Cooperative Oncology Group Performance
Status.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t2"><label>Table 2</label><caption><title>Efficacy Results in Intent to Treatment Population (ITT)</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">Chemotherapy plus rmhTNF N = 265 No. (%)</th><th align="center" valign="top" charoff="50">Chemotherapy N = 264 No. (%)</th><th align="center" valign="top" charoff="50">Odds Ratio (95% CI)</th><th align="center" valign="top" charoff="50">p value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Survival rate</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;1 year</td><td align="char" valign="top" char="(" charoff="50">147 (55.5)</td><td align="char" valign="top" char="(" charoff="50">111 (42)</td><td align="char" valign="top" char="(" charoff="50">1.717 (1.217-2.422)</td><td align="char" valign="top" char="." charoff="50">0.002</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;2 years</td><td align="char" valign="top" char="(" charoff="50">55 (20.8)</td><td align="char" valign="top" char="(" charoff="50">53 (20.1)</td><td align="char" valign="top" char="(" charoff="50">1.043 (0.683-1.591)</td><td align="char" valign="top" char="." charoff="50">0.846</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;3 years</td><td align="char" valign="top" char="(" charoff="50">37 (14)</td><td align="char" valign="top" char="(" charoff="50">28 (10.6)</td><td align="char" valign="top" char="(" charoff="50">1.368 (0.81-2.309)</td><td align="char" valign="top" char="." charoff="50">0.24</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;4 years</td><td align="char" valign="top" char="(" charoff="50">18 (6.8)</td><td align="char" valign="top" char="(" charoff="50">1 (0.4)</td><td align="char" valign="top" char="(" charoff="50">19.166 (2.54-144.645)</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">Response</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;RR (CR+PR)</td><td align="char" valign="top" char="(" charoff="50">102 (38.5)</td><td align="char" valign="top" char="(" charoff="50">73 (27.7)</td><td align="char" valign="top" char="(" charoff="50">1.637 (1.135-2.361)</td><td align="char" valign="top" char="." charoff="50">0.008</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;CR</td><td align="char" valign="top" char="(" charoff="50">4 (1.5)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">/</td><td align="char" valign="top" char="." charoff="50">0.045</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PR</td><td align="char" valign="top" char="(" charoff="50">98 (37)</td><td align="char" valign="top" char="(" charoff="50">73 (27.7)</td><td align="char" valign="top" char="(" charoff="50">1.535 (1.063-2.217)</td><td align="char" valign="top" char="." charoff="50">0.022</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;SD</td><td align="char" valign="top" char="(" charoff="50">105 (39.6)</td><td align="char" valign="top" char="(" charoff="50">117 (44.3)</td><td align="char" valign="top" char="(" charoff="50">0.825 (0.583-1.165)</td><td align="char" valign="top" char="." charoff="50">0.274</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PD</td><td align="char" valign="top" char="(" charoff="50">58 (21.9)</td><td align="char" valign="top" char="(" charoff="50">74 (28)</td><td align="char" valign="top" char="(" charoff="50">0.719 (0.484-1.069)</td><td align="char" valign="top" char="." charoff="50">0.103</td></tr><tr><td align="left" valign="top" charoff="50">Response duration (Month)</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;First quartile</td><td align="center" valign="top" charoff="50">3.6</td><td align="center" valign="top" charoff="50">2.8</td><td align="center" valign="top" charoff="50">/</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Median</td><td align="center" valign="top" charoff="50">5.8</td><td align="center" valign="top" charoff="50">4.1</td><td align="center" valign="top" charoff="50">/</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Third quartile</td><td align="center" valign="top" charoff="50">11</td><td align="center" valign="top" charoff="50">9.8</td><td align="center" valign="top" charoff="50">/</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>RR: Response Rate, CR: Complete Response, PR: Partial
Response, SD: Stable Disease, PD: Progressive Disease, RR =
CR+PR, CI: Confidence Intervals.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t3"><label>Table 3</label><caption><title>Summary of Reported Adverse Events (AEs) by Grade</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="3" align="center" valign="top" charoff="50">Chemotherapy plus rmhTNF (n =
261)</th><th colspan="3" align="center" valign="top" charoff="50">Chemotherapy (n = 259)</th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="center" valign="top" charoff="50">All Grade No. (%)</th><th align="center" valign="top" charoff="50">Grade 3 No. (%)</th><th align="center" valign="top" charoff="50">Grade 4 No. (%)</th><th align="center" valign="top" charoff="50">All Grade No. (%)</th><th align="center" valign="top" charoff="50">Grade 3 No. (%)</th><th align="center" valign="top" charoff="50">Grade 4 No. (%)</th></tr></thead><tbody valign="top"><tr><td colspan="7" align="center" valign="top" charoff="50">AEs Experienced by &#x0003e;10% of
Patients</td></tr><tr><td align="left" valign="top" charoff="50">Diarrhea</td><td align="char" valign="top" char="(" charoff="50">256 (97)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">259 (98)</td><td align="char" valign="top" char="(" charoff="50">3 (1.1)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Rash</td><td align="char" valign="top" char="(" charoff="50">256 (97)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">2 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">264 (100)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Albuminuria</td><td align="char" valign="top" char="(" charoff="50">255 (96)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">262 (99)</td><td align="char" valign="top" char="(" charoff="50">2 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Arrhythmia</td><td align="char" valign="top" char="(" charoff="50">254 (96)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">262 (99)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Infection (Non-neutropenia)</td><td align="char" valign="top" char="(" charoff="50">246 (93)</td><td align="char" valign="top" char="(" charoff="50">2 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">262 (99)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">ALT Increase</td><td align="char" valign="top" char="(" charoff="50">246 (93)</td><td align="char" valign="top" char="(" charoff="50">5 (2)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">248 (94)</td><td align="char" valign="top" char="(" charoff="50">8 (3)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">AST Increase</td><td align="char" valign="top" char="(" charoff="50">234 (89)</td><td align="char" valign="top" char="(" charoff="50">3 (1)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">247 (94)</td><td align="char" valign="top" char="(" charoff="50">2 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td></tr><tr><td align="left" valign="top" charoff="50">Stomatitis</td><td align="char" valign="top" char="(" charoff="50">246 (93)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">264 (100)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Thrombocytopenia</td><td align="char" valign="top" char="(" charoff="50">207 (78)</td><td align="char" valign="top" char="(" charoff="50">8 (3)</td><td align="char" valign="top" char="(" charoff="50">5 (2)</td><td align="char" valign="top" char="(" charoff="50">182 (69)</td><td align="char" valign="top" char="(" charoff="50">13 (5)</td><td align="char" valign="top" char="(" charoff="50">11 (4)</td></tr><tr><td align="left" valign="top" charoff="50">Fatigue</td><td align="char" valign="top" char="(" charoff="50">185 (70)</td><td align="char" valign="top" char="(" charoff="50">5 (2)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">169 (64)</td><td align="char" valign="top" char="(" charoff="50">4 (1)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Myalgia</td><td align="char" valign="top" char="(" charoff="50">185 (70)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">259 (98)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Flu-like symptoms</td><td align="char" valign="top" char="(" charoff="50">170 (64)</td><td align="char" valign="top" char="(" charoff="50">10 (4)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">264 (100)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Pyrexia</td><td align="char" valign="top" char="(" charoff="50">162 (61)</td><td align="char" valign="top" char="(" charoff="50">16 (6)</td><td align="char" valign="top" char="(" charoff="50">8 (3)</td><td align="char" valign="top" char="(" charoff="50">248 (94)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Neutropenia</td><td align="char" valign="top" char="(" charoff="50">133 (50)</td><td align="char" valign="top" char="(" charoff="50">34 (13)</td><td align="char" valign="top" char="(" charoff="50">8 (3)</td><td align="char" valign="top" char="(" charoff="50">121 (46)</td><td align="char" valign="top" char="(" charoff="50">21 (8)</td><td align="char" valign="top" char="(" charoff="50">16 (6)</td></tr><tr><td align="left" valign="top" charoff="50">Leukopenia</td><td align="char" valign="top" char="(" charoff="50">122 (46)</td><td align="char" valign="top" char="(" charoff="50">29 (11)</td><td align="char" valign="top" char="(" charoff="50">13 (5)</td><td align="char" valign="top" char="(" charoff="50">66 (25)</td><td align="char" valign="top" char="(" charoff="50">24 (9)</td><td align="char" valign="top" char="(" charoff="50">13 (5)</td></tr><tr><td align="left" valign="top" charoff="50">Nausea</td><td align="char" valign="top" char="(" charoff="50">117 (44)</td><td align="char" valign="top" char="(" charoff="50">8 (3)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">63 (24)</td><td align="char" valign="top" char="(" charoff="50">24 (9)</td><td align="char" valign="top" char="(" charoff="50">3 (1)</td></tr><tr><td align="left" valign="top" charoff="50">Vomiting</td><td align="char" valign="top" char="(" charoff="50">115 (43)</td><td align="char" valign="top" char="(" charoff="50">5 (2)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">58 (22)</td><td align="char" valign="top" char="(" charoff="50">15 (6)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Abdominal Pain</td><td align="char" valign="top" char="(" charoff="50">87 (33)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">74 (28)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Chest Pain</td><td align="char" valign="top" char="(" charoff="50">85 (32)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">58 (22)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td colspan="7" align="center" valign="top" charoff="50">AEs of Special Interest</td></tr><tr><td align="left" valign="top" charoff="50">Myalgia</td><td align="char" valign="top" char="(" charoff="50">185 (70)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">259 (98)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Flu-like symptoms<xref ref-type="fn" rid="t3-fn1">*</xref></td><td align="char" valign="top" char="(" charoff="50">170 (64)</td><td align="char" valign="top" char="(" charoff="50">10 (4)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">264 (100)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Pyrexia<xref ref-type="fn" rid="t3-fn1">*</xref></td><td align="char" valign="top" char="(" charoff="50">162 (61)</td><td align="char" valign="top" char="(" charoff="50">16 (6)</td><td align="char" valign="top" char="(" charoff="50">8 (3)</td><td align="char" valign="top" char="(" charoff="50">248 (94)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Febrile Neutropenia</td><td align="char" valign="top" char="(" charoff="50">16 (6)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">21 (8)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Hematemesis <xref ref-type="fn" rid="t3-fn1">*</xref></td><td align="char" valign="top" char="(" charoff="50">16 (6)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">3 (1)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Hypotension</td><td align="char" valign="top" char="(" charoff="50">2 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">2 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Pulmonary Embolus</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Cardiac event</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">1 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td><td align="char" valign="top" char="(" charoff="50">2 (&#x0003c;1)</td><td align="char" valign="top" char="(" charoff="50">2 (&#x0003c;1)</td><td align="center" valign="top" charoff="50">0</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>ALT: Alanine Transaminase, AST: Aspartate Aminotransferase,
*p&#x0003c;0.05 Comparison of Grade 3 and 4.</p></fn></table-wrap-foot></table-wrap></floats-group></article>